Federal Register of Legislation - Australian Government

Primary content

PB 24 of 2012 Specifications as made
This instrument amends the National Health (Pharmaceutical Benefits - Early Supply) Instrument 2009 - specification under subsection 84AAA(2) (No. PB 30 of 2009) to insert two new pharmaceutical items, delete an existing pharmaceutical item, and amend an existing pharmaceutical item.
Administered by: Health
Registered 29 Mar 2012
Tabling HistoryDate
Tabled HR08-May-2012
Tabled Senate10-May-2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

 

COMMONWEALTH OF AUSTRALIA

Instrument number PB 24 of 2012

National Health Act (Pharmaceutical Benefits – Early Supply) Amendment April 2012 - specification under subsection 84AAA(2)1

 

Amendment determination under subsection 84AAA(2) of the National Health Act 1953

 

I, Adriana Platona, Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

 

Dated         23 March 2012

 

 

ADRIANA PLATONA

Assistant Secretary

Pharmaceutical Evaluation Branch

Department of Health and Ageing

 

 

 

Amendment determination — Pharmaceutical Benefits - Early Supply

 

 

1          Name of Instrument

 

(1)           This Instrument is the National Health Act (Pharmaceutical Benefits – Early Supply) Amendment April 2012 - specification under subsection 84AAA(2).

 

(2)           This Instrument may also be cited as No. PB 24 of 2012.


 

2          Commencement

 

This Instrument commences on 1 April 2012.

 

 

3          Amendment of PB 30 of 2009

 

Schedule 1 amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 - specification under subsection 84AAA(2), PB 30 of 2009.

 


Schedule 1        Amendments

[1]                       Schedule 1, before item dealing with Aciclovir

insert in the columns in the order indicated:

 

Abatacept

Injection 125 mg in 1 mL single dose pre-filled syringe

Injection

4

5

 

 

[2]                       Schedule 1, after item dealing with Nifedipine

insert in the columns in the order indicated:

 

Nilotinib

Capsule 150 mg (as hydrochloride monohydrate)    

Oral

120

5

 

 

[3]                       Schedule 1, item dealing with Oestradiol

Omit from the columns in the order indicated:

 

 

Transdermal patches 8 mg, 8

Transdermal

1

5

 

 

[4]                       Schedule 1, item dealing with Nilotinib, Capsule 200 mg (as hydrochloride monohydrate)

omit from the column headed “Maximum quantity or number of units”:

112

and substitute:

120

 

1Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.frli.gov.au.